Amgen (AMGN) Peer Comparison
$416.65
$9.21
(2.26%)
As on 09-Oct-2026 13:34EDT
Market cap
$217,896 Mln
Revenue (TTM)
$38,125 Mln
P/E Ratio
25.3
P/B Ratio
18.8
Div. Yield
2.4 %
Edit
| Amgen (AMGN) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
217,896 | 1,042,981 | 618,091 | 481,398 | 351,276 |
Revenue ($ Mln) |
38,125 | 79,666 | 97,929 | 64,386 | 66,400 |
Net Profit ($ Mln) |
8,743.00 | 26,711.20 | 21,037.00 | 6,314.00 | 3,173.00 |
Net Margin (%) |
22.93 | 33.53 | 21.48 | 9.81 | 4.78 |
RoE (%) |
85.94 | 88.43 | 25.27 | -- | 6.72 |
Price to Earnings |
25.32 | 39.26 | 29.96 | 76.95 | 113.00 |
Price-To-Book |
18.78 | 30.28 | 7.63 | 50.46 | 8.71 |
Income Statement ($ Mln)
| Amgen (AMGN) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
38,125.00 | 79,665.80 | 97,929.00 | 64,386.00 | 66,400.00 |
|
Cost of Revenue
|
10,427.00 | 13,225.00 | 31,428.00 | 18,365.00 | 16,350.00 |
|
Gross Profit
|
26,012.00 | 54,127.00 | 63,937.00 | 42,956.00 | 46,731.00 |
|
Operating Expenses
|
15,050.00 | 26,832.30 | 40,245.00 | 27,142.00 | 38,994.00 |
|
Operating Profit (EBIT)
|
12,648.00 | 39,608.50 | 26,256.00 | 18,879.00 | 11,056.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
10,287.00 | 33,595.60 | 25,196.00 | 8,699.00 | 5,948.00 |
|
Provision for Tax
|
1,544.00 | 6,884.40 | 4,159.00 | 2,383.00 | 2,779.00 |
|
Profit after Tax (Net Income)
|
8,743.00 | 26,711.20 | 21,037.00 | 6,314.00 | 3,173.00 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | -6.00 | 4.00 |
|
Consolidated Profit
|
0.00 | 12,218.50 | 10,268.00 | 0.00 | 8,748.00 |
Liabilities ($ Mln)
| Amgen (AMGN) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
11,688.00 | 33,879.00 | 84,971.00 | -5,935.00 | 41,933.00 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | -6.00 | 4.00 |
|
Non-Current Liabilities
|
58,449.00 | 60,663.00 | 61,195.00 | 99,361.00 | 60,087.00 |
|
Current Liabilities
|
25,502.00 | 47,741.00 | 54,895.00 | 41,642.00 | 27,731.00 |
|
Total Liabilities
|
90,586.00 | 112,476.00 | 199,210.00 | 133,960.00 | 136,866.00 |
Assets ($ Mln)
| Amgen (AMGN) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
60,678.00 | 77,611.00 | 141,286.00 | 101,446.00 | 93,123.00 |
|
Current Assets
|
34,961.00 | 64,672.00 | 59,774.00 | 33,669.00 | 36,679.00 |
|
Total Assets
|
90,586.00 | 112,476.00 | 199,210.00 | 133,960.00 | 136,866.00 |
|
Total Debt*
|
57,304.00 | 54,908.00 | 49,036.00 | 70,822.00 | 53,906.00 |
|
Net Current Assets
|
9,459.00 | 16,931.00 | 4,879.00 | -7,973.00 | 8,948.00 |
Cashflow ($ Mln)
| Amgen (AMGN) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
9,958.00 | 16,813.00 | 24,530.00 | 19,030.00 | 16,472.00 |
|
Cash Flow from Investing Activities
|
-1,943.00 | -10,972.00 | -23,588.00 | -6,643.00 | -13,741.00 |
|
Cash from Financing Activities
|
-10,859.00 | -2,213.00 | -5,539.00 | -12,724.00 | -1,922.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Amgen (AMGN) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
11.93 | 35.32 | 22.56 | 6.17 | 19.45 |
|
ROE (%)
|
85.94 | 88.43 | 25.27 | 6,214.71 | 6.72 |
|
ROA (%)
|
7.62 | 16.19 | 8.36 | 3.57 | 2.11 |
|
EBIT Margin (%)
|
33.98 | 51.72 | 26.53 | 20.68 | 10.86 |
|
Net Margin (%)
|
22.93 | 33.53 | 21.48 | 9.81 | 4.78 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Amgen (AMGN) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
9.23 | 49.58 | 8.06 | 10.39 | 4.24 |
|
EBIT Growth (%)
|
24.83 | 112.76 | -7.83 | 125.97 | -64.72 |
|
Net Profit Growth (%)
|
32.09 | 93.56 | -7.17 | 67.79 | -80.66 |
|
EPS Growth (%)
|
31.70 | 94.63 | -7.72 | 67.77 | -80.70 |
|
Book Value Growth (%)
|
56.48 | 86.67 | 7.35 | -4,203.16 | -12.99 |
Valuation Ratios
| Amgen (AMGN) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
23.05 | 46.76 | 18.83 | 95.92 | 14.35 |
|
Price / Book Value
|
20.53 | 30.28 | 7.63 | 50.46 | 8.71 |
|
Dividend Yield (%)
|
-- | 0.54 | 2.03 | 2.52 | 2.33 |
|
EV/EBITDA
|
13.21 | 24.90 | 19.15 | 25.74 | 27.81 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Amgen (AMGN) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
4.44 | 1.41 | 0.44 | -10.53 | 1.22 |
|
Short term debt to equity ratio
|
0.47 | 0.21 | 0.14 | -1.41 | 0.07 |
|
Current Ratio
|
1.37 | 1.35 | 1.09 | 0.81 | 1.32 |
|
Quick Ratio
|
1.13 | 1.00 | 0.81 | 0.69 | 1.10 |
|
Interest Coverage
|
4.86 | 35.30 | 25.90 | 3.98 | 4.41 |
Operating Efficiency Ratios
| Amgen (AMGN) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
26.82 | 29.47 | 19.45 | 21.47 | 18.92 |
|
Asset Turnover
|
0.33 | 0.48 | 0.39 | 0.36 | 0.44 |
|
Receivable days
|
84.85 | 93.67 | 70.00 | 70.20 | 64.57 |
|
Inventory Days
|
225.08 | 352.51 | 160.77 | 91.61 | 128.14 |
|
Payable days
|
72.77 | 142.23 | 134.61 | 65.58 | 85.14 |
|
Cash Conversion Cycle
|
237.16 | 303.95 | 96.16 | 96.23 | 107.57 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
